original ) (raw )Analyzing the role of the immune system and Immunotherapy in Triple Negative Breast Cancer (TNBC) Management
The Journal of Middle East and North Africa Sciences
The Journal of Middle East and North Africa Sciences, 2022
View PDFchevron_right
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?
Barbara Politynska
Cancer and Metastasis Reviews, 2022
View PDFchevron_right
The role of immune checkpoint inhibitors in triplenegative breast cancer: recent developments and future perspectives
Journal of Cancer Metastasis and Treatment
Journal of Cancer Metastasis and Treatment, 2021
View PDFchevron_right
Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice
Francesca Carlino
Cancers
View PDFchevron_right
A narrative review of immune checkpoint inhibitors in early stage triple negative breast cancer
Terry En Gee
2021
View PDFchevron_right
Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer
Semir Vranić , BJBMS Journal
Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer, 2019
View PDFchevron_right
Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
Anastasia Constantinidou
Frontiers in Genetics
View PDFchevron_right
An overview of immune checkpoint inhibitors in breast cancer
Nicla La Verde
Exploration of Targeted Anti-tumor Therapy
View PDFchevron_right
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Beatriz Henriques
Biomedicines
View PDFchevron_right
Differential expression of novel immune checkpoint receptors on tumor-infiltrating lymphocytes in patients with locally advanced breast cancer after neoadjuvant chemotherapy
Mustafa Tükenmez
Neoplasma, 2021
View PDFchevron_right
Current Landscape of Immunotherapy in Breast Cancer
Jane Perlmutter
JAMA Oncology, 2019
View PDFchevron_right
Immune checkpoints in aggressive breast cancer subtypes
Izabela Zawlik
Neoplasma, 2016
View PDFchevron_right
What is the role of immunotherapy in breast cancer?
JACK CHAN
Chinese clinical oncology, 2018
View PDFchevron_right
Immunotherapy in Triple-Negative Breast Cancer: Present and Future
Tatiana Vidaurre
Current Breast Cancer Reports, 2019
View PDFchevron_right
Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects
aayushi shah
Medical Oncology
View PDFchevron_right
Targeting immune checkpoints in breast cancer: an update of early results
Cinzia Solinas
ESMO Open, 2017
View PDFchevron_right
The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
Małgorzata Bajor
Cancers
View PDFchevron_right
Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives
Lamiae AMAADOUR
International Journal of Breast Cancer, 2020
View PDFchevron_right
Tumor-Infiltrating Lymphocytes and Breast Cancer: Are Immune Checkpoint Inhibitors Ready for Prime Time in Breast Cancer?
Miloš Kostić
Acta Facultatis Medicae Naissensis, 2016
View PDFchevron_right
Immunotherapy in triple-negative breast cancer: A literature review and new advances
Tatiana Vidaurre
World journal of clinical oncology, 2022
View PDFchevron_right
A Retrospective Look at Immunotherapy: Where We Are Now and The Future It Holds for Breast Cancer Patients
Abdul Rashid Abdulai
View PDFchevron_right
Immunology and immunotherapy in breast cancer
Anna Artemyeva
Cancer Biology & Medicine
View PDFchevron_right
Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology
Roberto Piciotti
Anti-Cancer Agents in Medicinal Chemistry, 2022
View PDFchevron_right
Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients (ex-vivo study)
Dr.Enas Radwan
Oncology Research
View PDFchevron_right
Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors
Eriseld Krasniqi
Immunotherapy, 2020
View PDFchevron_right
Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
Guilherme Mesquita
Breast Cancer: Targets and Therapy, 2021
View PDFchevron_right
Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
Emilie Mamessier
OncoImmunology
View PDFchevron_right
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: A Biomarker for Use Beyond Prognosis?
Sandro Casavilca-Zambrano
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015
View PDFchevron_right
Immunotherapy: A Challenge of Breast Cancer Treatment
Marilina García Aranda
Cancers, 2019
View PDFchevron_right
Impact of tumor-infiltrating lymphocytes on pathological complete response after neoadjuvant chemotherapy in patients with early triple-negative breast cancer
Mustapha Oumouna
Medica Jadertina, 2021
View PDFchevron_right
Tumor infiltrating lymphocytes in triple negative breast cancer and correlations with prognosis
Patrizia Querzoli
Annals of Oncology, 2016
View PDFchevron_right
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting
Henry Gomez
Clinical Medicine Insights: Oncology, 2016
View PDFchevron_right